FDA Inspection 1144657 — Homeocare Laboratories, Inc.

Homeocare Laboratories, Inc. — FEI 3008420443

The FDA completed an inspection of Homeocare Laboratories, Inc. on June 4, 2021 in Yonkers, NY. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 9 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
June 4, 2021
Fiscal Year
2021
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Yonkers, NY (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
113321 CFR 211.25(a)GMP Training Frequency
121321 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
121521 CFR 211.67(b)Written procedures not established/followed
125121 CFR 211.42(c)(1)Incoming material area
135821 CFR 211.100(b)SOPs not followed / documented
136121 CFR 211.100(a)Absence of Written Procedures
192821 CFR 211.166(c)(1)Homeopathic drugs, assessment of stability
360321 CFR 211.160(b)Scientifically sound laboratory controls